Clonidine ER

• ADHD (Attention-Deficit/Hyperactivity Disorder)
• Pediatric ADHD
• Non-Stimulant ADHD Treatment
• Adjunctive ADHD Therapy

Clonidine extended-release (ER) is an alpha-2 adrenergic agonist formulated specifically for the treatment of attention-deficit/hyperactivity disorder (ADHD). This non-stimulant medication provides an alternative or adjunctive treatment option for patients who cannot tolerate or have an inadequate response to stimulant medications.

Mechanism of Action

Clonidine ER acts as an agonist at alpha-2 adrenergic receptors in the brain, particularly in the prefrontal cortex. Stimulation of post-synaptic alpha-2A receptors in the prefrontal cortex strengthens working memory and attention regulation. Additionally, alpha-2 agonism in the locus coeruleus reduces norepinephrine release, contributing to decreased hyperactivity and impulsivity. The mechanism in ADHD differs from clonidine's antihypertensive action, which is primarily mediated through presynaptic alpha-2 receptors in the brainstem that reduce sympathetic outflow. The extended-release formulation provides more consistent plasma levels and allows once or twice daily dosing.

Available Formulations

Clonidine ER for ADHD is available as extended-release tablets in 0.1 mg and 0.2 mg strengths. These tablets must be swallowed whole and should not be crushed, chewed, or broken, as this destroys the extended-release mechanism. This formulation is distinct from immediate-release clonidine tablets and the transdermal patch, which are primarily used for hypertension. The ADHD formulation should not be substituted with other clonidine products.

Medical Uses

Clonidine ER is FDA-approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. It can be used as monotherapy or as adjunctive therapy to stimulant medications. The medication is particularly useful for patients with comorbid conditions such as tic disorders, oppositional behaviors, or sleep difficulties, where stimulants may be problematic. Clinical trials demonstrated improvements in ADHD symptoms as measured by ADHD Rating Scale-IV scores.

Dosing Guidelines

Treatment should be initiated with 0.1 mg at bedtime. The dose should be increased in increments of 0.1 mg/day at weekly intervals until the desired response is achieved, up to a maximum of 0.4 mg/day. Doses should be given either as a single daily dose (at bedtime) or divided into twice-daily doses (morning and bedtime), with the higher dose at bedtime if unequal split dosing is used. When discontinuing, the dose should be tapered in decrements of 0.1 mg every 3-7 days to avoid rebound hypertension.

Important Safety Information

Clonidine ER causes dose-dependent decreases in blood pressure and heart rate; patients should have blood pressure and pulse monitored regularly, especially during dose initiation and adjustment. The medication should be used with caution in patients with cardiovascular disease, history of hypotension, bradycardia, syncope, or heart block. Abrupt discontinuation can cause rebound hypertension. Sedation and somnolence are common, particularly during initial treatment. The extended-release tablets must be swallowed whole.

Drug Interactions

Concomitant use with CNS depressants (alcohol, sedatives, opioids) may enhance sedation. Tricyclic antidepressants may reduce clonidine's antihypertensive effect. Beta-blockers may potentiate bradycardia and AV block. Drugs that affect sinus node function or AV nodal conduction (digoxin, calcium channel blockers) should be used with caution. CYP2D6 inhibitors may affect clonidine metabolism, though clinical significance is unclear.

Where Clonidine ER Fits in ADHD Treatment

Clonidine ER is seldom the first medication tried for attention-deficit/hyperactivity disorder (ADHD). Stimulants remain the most effective class and are the usual starting point, so clonidine ER is reached for in three recognizable situations. The first is a child who cannot tolerate stimulants — appetite loss with poor growth, rebound irritability in the late afternoon, worsening anxiety, or emergence of tics. The second is a child whose stimulant works well during the day but whose evening behavior, aggression, or sleep onset remains unmanageable; here clonidine ER is added to the stimulant rather than replacing it, and the combination is an approved use. The third is a family that declines a controlled substance.

Among the non-stimulants, the closest comparison is guanfacine ER, which acts on the same alpha-2 receptor family but is more selective for the alpha-2A subtype and is generally less sedating; clonidine ER is often the better choice when sedation is wanted for sleep onset, and guanfacine ER when daytime drowsiness must be avoided. Atomoxetine works through norepinephrine reuptake inhibition instead and is often preferred when anxiety is prominent. None of the non-stimulants matches the effect size of methylphenidate or amphetamine-dextroamphetamine on core inattention.

The First Weeks and What Makes It Fail

Sedation is the defining feature of the first two weeks and is the reason most families stop early. It is usually worst in the afternoon after a morning dose and it usually fades; warning families that it is expected, and that it is temporary, prevents most early discontinuations. Giving the larger share of the dose at bedtime uses the sedation rather than fighting it. Benefit on behavior builds gradually over weeks rather than appearing on the first day, which is a different experience from a stimulant and should be described in advance so the family is not waiting for something immediate.

Three other things account for most failures. Doses are increased too quickly, producing dizziness and drowsiness that could have been avoided by waiting the full interval between steps. The extended-release tablet is crushed or split for a child who cannot swallow pills, which destroys the release mechanism and delivers the dose all at once. And the medication is stopped abruptly when a prescription lapses or a family decides it is not working, which can produce rebound hypertension, agitation, and headache; a taper is needed even after short courses. Blood pressure and pulse are checked at baseline and at each dose change. The MedlinePlus clonidine monograph and the NIMH overview of ADHD cover the treatment options for families. Adults whose symptoms were never identified in childhood are discussed in our article on recognizing adult ADHD later in life, and our psychiatric colleagues help when mood, anxiety, or tic disorders complicate the picture.

Special Populations

There are no adequate studies of clonidine ER in pregnant women; use only if clearly needed. Clonidine is excreted in breast milk; caution is advised during breastfeeding. Safety and efficacy have been established in pediatric patients aged 6-17 years; clonidine ER has not been studied in children under 6 or adults with ADHD. Elderly patients are not typically treated for ADHD with this medication. Patients with renal impairment may require dose adjustment; clonidine is primarily renally eliminated. Use with caution in hepatic impairment.